Lyra therapeutics announces two presentations at upcoming cosm 2022

Lyr-210 data on impact of long-acting implantable corticosteroid matrices in patients with crs selected as a top clinical abstract both presentations demonstrate potential benefit of lyr-210 to chronic rhinosinusitis patients watertown, mass. , april 21, 2022 /prnewswire/ -- lyra therapeutics, inc. (nasdaq: lyra), a clinical-stage therapeutics company leveraging its proprietary xtreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ent) passages and other diseased tissues, today announced that two new abstracts highlighting additional lantern study data evaluating lyr-210 in chronic rhinosinusitis (crs) have been selected for podium presentations at the upcoming 2022 combined otolaryngology spring meetings (cosm) being held april 27 – may 1, 2022 in dallas, texas.
LYRA Ratings Summary
LYRA Quant Ranking